MedTrace Logo

Mirtazapine to Reduce Methamphetamine Use Among MSM With High-risk HIV Behaviors

NCT00497081 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2015-01-05

Study results available
· View outcomes & findings →

Summary

Studies demonstrate that methamphetamine (meth) use is associated with high-risk sexual behavior among MSM, putting meth-using MSM at extraordinarily high risk for transmitting or acquiring HIV. This study of intermediate size (60 participants) and length (3 months of follow-up) will assess the efficacy of mirtazapine in reducing methamphetamine use among high-risk MSM.

Conditions

Interventions

DRUG

mirtazapine

mirtazapine 30 mg daily for 3 months

DRUG

placebo

placebo 30 mg daily for 3 months

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Public Health Foundation Enterprises, Inc.

    collaborator OTHER

  • San Francisco Department of Public Health

    lead OTHER_GOV

Principal Investigators

  • Grant N Colfax, MD · Co-Directior, HIV Epidemiology Section, San Francisco Department of Public Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00497081 on ClinicalTrials.gov